SX-517
Modify Date: 2025-08-25 17:15:22
SX-517 structure
|
Common Name | SX-517 | ||
|---|---|---|---|---|
| CAS Number | 1240494-13-6 | Molecular Weight | 382.216 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C19H16BFN2O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SX-517A potent, specific, noncompetitive dual CXCR1 and CXCR2 antagonist with IC50 of 38 nM (vs. CXCL1) and 36 nM (vs. CXCL8), respectively; inhibits CXCL1-induced Ca(2+) flux in human PMNs but has no effect on the Ca(2+) flux induced by C5a, fMLF, or PAF; antagonizes CXCL8-induced [(35)S]GTPγS binding (IC50=60 nM) and ERK1/2 phosphorylation in recombinant HEK293 cells expressed CXCR2; significantly inhibits inflammation in an in vivo murine model (0.2 mg/kg iv). |
| Name | SX-517 |
|---|---|
| Synonym | More Synonyms |
| Description | A potent, specific, noncompetitive dual CXCR1 and CXCR2 antagonist with IC50 of 38 nM (vs. CXCL1) and 36 nM (vs. CXCL8), respectively; inhibits CXCL1-induced Ca(2+) flux in human PMNs but has no effect on the Ca(2+) flux induced by C5a, fMLF, or PAF; antagonizes CXCL8-induced [(35)S]GTPγS binding (IC50=60 nM) and ERK1/2 phosphorylation in recombinant HEK293 cells expressed CXCR2; significantly inhibits inflammation in an in vivo murine model (0.2 mg/kg iv). |
|---|---|
| References | References 1. Maeda DY, et al. J Med Chem. 2014 Oct 23;57(20):8378-97. 2. Schuler AD, et al.Bioorg Med Chem Lett. 2015 Sep 15;25(18):3793-7. View Related Products by Target Chemokine Receptor (CCR and CXCR) |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C19H16BFN2O3S |
| Molecular Weight | 382.216 |
| Exact Mass | 382.095886 |
| LogP | 3.98 |
| Index of Refraction | 1.663 |
| InChIKey | VZRIHFZJVIOJBE-UHFFFAOYSA-N |
| SMILES | O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 |
| Boronic acid, B-[2-[[[5-[[(4-fluorophenyl)amino]carbonyl]-2-pyridinyl]thio]methyl]phenyl]- |
| {2-[({5-[(4-Fluorophenyl)carbamoyl]-2-pyridinyl}sulfanyl)methyl]phenyl}boronic acid |
| SX-517 |